| 降糖药利拉鲁肽及其临床评价 |
| |
| 引用本文： | 徐华.降糖药利拉鲁肽及其临床评价[J].世界临床药物,2008,29(11):651-655. |
| |
| 作者姓名： | 徐华 |
| |
| 作者单位： | 上海交通大学医学院附属仁济医院内分泌科 |
| |
| 摘 要： | 利拉鲁肽(Iiraglutide)是新一代以肠促胰素为基础的降糖药,具有良好的降糖效果,无论单独应用还是与其他口服降糖药联用,均能迅速、高效地降低血糖和糖化血红蛋白(HbA1c)水平.其降糖作用依赖于葡萄糖浓度,即仅在血糖水平升高时刺激胰岛素释放达到治疗效果,因此发生低血糖的概率非常低.此外,利拉鲁肽能改善B细胞功能,降低血压,延缓糖尿病进展,减低糖尿病心血管并发症危险.与其他大多数降糖药相比,利拉鲁肽能帮助患者减轻体重.利拉鲁肽具有超越现有糖尿病治疗药物的多种特点.
|
| 关 键 词： | 利拉鲁肽 胰高血糖素样肽-1 2型糖尿病 |
Clinical evaluation of liraglutide |
| |
| XU Hua.Clinical evaluation of liraglutide[J].WORLD CLINICAL DRUGS,2008,29(11):651-655. |
| |
| Authors: | XU Hua |
| |
| Institution: | XU Hua(Department of Endocrinology,Ren Ji Hospital,Shanghai Jiao Tong University,Shanghai 200001,China) |
| |
| Abstract: | Liraglutide, a novel glucagon-like peptide-1(GLP-1) analogue is used for type 2 diabetes therapy once daily by subcutaneously injection.It can reduce hemoglobin A1c(HbA1c), fasting and postprandial glucose no matter used as monotherapy or combined with other oral antidiabetic drugs.Since its action of reducing blood glucose is based on glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion, liraglutide causes few hypoglycemia event.In addition, it can improve the function of... |
| |
| Keywords: | liraglutide glucagon-like peptide-1 type 2 diabetes |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
